Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19564500 | 0.86 | HCRTR2 (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL19549823 | 0.86 | HCRTR2 (0.45) | HCRTR2HCRTR1 | |
| SCHEMBL27030050 | 0.85 | HCRTR2 (0.56) | HCRTR2HCRTR1 | |
| SCHEMBL30986121 | 0.85 | HCRTR2 (0.56) | HCRTR2HCRTR1 | |
| SCHEMBL17847215 | 0.82 | HCRTR2 (0.60) | HCRTR2HCRTR1 | |
| SCHEMBL19565854 | 0.82 | HCRTR2 (0.60) | HCRTR2HCRTR1 | |
| SCHEMBL17842637 | 0.79 | HCRTR2 (0.59) | HCRTR2HCRTR1 | |
| SCHEMBL2291824 | 0.79 | HCRTR2 (0.65) | HCRTR2HCRTR1 | |
| SCHEMBL7915973 | 0.79 | HCRTR2 (0.65) | HCRTR2HCRTR1 | |
| SCHEMBL7918180 | 0.79 | HCRTR2 (0.65) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2016100157-A2 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.